Metastatic Breast Cancer Top Companies and Strategic Involvements

Latest Updates of Companies in the Metastatic Breast Cancer Market

Recent Developments in the Metastatic Breast Cancer Market

• In March 2026, Pfizer Inc. announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer who had received prior cyclin-dependent kinase (CDK) 4/6 inhibitor-based treatment.
• In December 2025, AstraZeneca and Daiichi Sankyo’s Enhertu, in combination with pertuzumab, has been approved in the US for the 1st-line management of adult patients with unresectable or metastatic HER2-positive breast cancer, as determined by a Food and Drug Administration (FDA)-driven test.

Supply Chain Analysis

R&D:

• Research and development (R&D) in RNA interference therapy includes molecular profiling and genomic evolution research, liquid biopsies and patient-based organoids, targeted therapy advancement, pre-metastatic niche and microenvironment studies, clinical trials, and real-world evidence.
• Key Players: Novartis and Sanofi

Manufacturing Processes:

• Manufacturing processes for RNA interference therapy involve epithelial-mesenchymal transition (EMT), intravasation, circulation and survival, pre-metastatic niche creation, extravasation and colonization, and metabolic reprogramming
• Key Players: Eli Lilly and AstraZeneca

Patient Services:

• Patient services involve palliative care, pain management, psychosocial support, nutritional counselling, integrative therapies, and patient navigation to clinical trials.
• Key Players: Roche and Pfizer

Market Growth

The global metastatic breast cancer market size was estimated at USD 22.8 billion in 2025 and is predicted to increase from USD 24.99 billion in 2026 to approximately USD 57.02 billion by 2035, expanding at a CAGR of 9.6% from 2026 to 2035. The metastatic breast cancer market is growing because metastatic breast cancer is a recurrent cancer, meaning it’s a cancer that came back after treatment and is affecting tissue and organs located far from the original breast cancer.